Radiological and pathological predictors of post-operative upstaging of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma and lymph-nodes metastasis; a potential algorithm for node surgical de-escalation.

DCIS Ductal carcinoma in situ Omitting SNLB Surgical de-escalation Upstaging

Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 21 09 2023
revised: 12 07 2024
accepted: 29 08 2024
medline: 7 9 2024
pubmed: 7 9 2024
entrez: 6 9 2024
Statut: aheadofprint

Résumé

Ductal carcinoma in situ is considered a local disease with no metastatic potential, thus sentinel lymph node biopsy (SLNB) may be deemed an overtreatment. SLNB should be reserved for patients with invasive cancer, even though the risk of upstaging rises to 25 %. We aimed to identify clinicopathological predictors of post-operative upstaging in invasive carcinoma. We retrospectively analyzed patients with a pre-operative diagnosis of DCIS subjected to breast surgery between January 2017 to December 2021, and evaluated at the Breast Unit of PTV (Policlinico Tor Vergata, Rome). Out of 267 patients diagnosed with DCIS, 33(12.4 %) received a diagnosis upstaging and 9(3.37 %) patients presented with sentinel lymph node (SLN) metastasis. In multivariate analysis, grade 3 tumor (OR 1.9; 95 % CI 1.2-5.6), dense nodule at mammography (OR 1.3; 95 % CI 1.1-2.6) and presence of a solid nodule at ultrasonography (OR 1.5; 95 % CI 1.2-2.6) were independent upstaging predictors. Differently, the independent predictors for SLNB metastasis were: upstaging (OR 2.1.; 95 % CI 1.2-4.6; p = 0.0079) and age between 40 and 60yrs (OR 1.4; 95 % CI 1.4-2.7; p = 0.027). All 9 patients with SLN metastasis received a diagnosis upstaging and were aged between 40 and 60 years old. We identified pre-operative independent predictors of upstaging to invasive ductal carcinoma. The combined use of different predictors in an algorithm for surgical treatments of DCIS could reduce the numbers of unnecessary SLNB.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Ductal carcinoma in situ is considered a local disease with no metastatic potential, thus sentinel lymph node biopsy (SLNB) may be deemed an overtreatment. SLNB should be reserved for patients with invasive cancer, even though the risk of upstaging rises to 25 %. We aimed to identify clinicopathological predictors of post-operative upstaging in invasive carcinoma.
METHODS METHODS
We retrospectively analyzed patients with a pre-operative diagnosis of DCIS subjected to breast surgery between January 2017 to December 2021, and evaluated at the Breast Unit of PTV (Policlinico Tor Vergata, Rome).
RESULTS RESULTS
Out of 267 patients diagnosed with DCIS, 33(12.4 %) received a diagnosis upstaging and 9(3.37 %) patients presented with sentinel lymph node (SLN) metastasis. In multivariate analysis, grade 3 tumor (OR 1.9; 95 % CI 1.2-5.6), dense nodule at mammography (OR 1.3; 95 % CI 1.1-2.6) and presence of a solid nodule at ultrasonography (OR 1.5; 95 % CI 1.2-2.6) were independent upstaging predictors. Differently, the independent predictors for SLNB metastasis were: upstaging (OR 2.1.; 95 % CI 1.2-4.6; p = 0.0079) and age between 40 and 60yrs (OR 1.4; 95 % CI 1.4-2.7; p = 0.027). All 9 patients with SLN metastasis received a diagnosis upstaging and were aged between 40 and 60 years old.
CONCLUSION CONCLUSIONS
We identified pre-operative independent predictors of upstaging to invasive ductal carcinoma. The combined use of different predictors in an algorithm for surgical treatments of DCIS could reduce the numbers of unnecessary SLNB.

Identifiants

pubmed: 39241490
pii: S0960-7404(24)00096-3
doi: 10.1016/j.suronc.2024.102128
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102128

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All the authors declare that they have no potential conflict of interest.

Auteurs

Gianluca Vanni (G)

Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Marco Pellicciaro (M)

Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy; Applied Medical-Surgical Sciences, Department of Surgical Science, Tor Vergata University, Rome, RM, Italy. Electronic address: marcopell62@gmail.com.

Marco Materazzo (M)

Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy; Applied Medical-Surgical Sciences, Department of Surgical Science, Tor Vergata University, Rome, RM, Italy.

Massimiliano Berretta (M)

Department of Clinical and Experimental Medicine, University of Messina, 98100, Messina, (ME), Italy.

Rosaria Meucci (R)

Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Tommaso Perretta (T)

Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Ilaria Portarena (I)

Department of Oncology, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Chiara Adriana Pistolese (CA)

Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Oreste Claudio Buonomo (OC)

Breast Unit Policlinico Tor Vergata, Department of Surgical Science, Tor Vergata University, Viale Oxford 81, 00133, Rome, (RM), Italy.

Classifications MeSH